Semanteon Capital Management LP Has $912,000 Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Semanteon Capital Management LP increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 88.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,247 shares of the biotechnology company’s stock after acquiring an additional 22,181 shares during the quarter. Semanteon Capital Management LP owned 0.08% of Innoviva worth $912,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. American Century Companies Inc. increased its stake in Innoviva by 369.6% in the second quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock valued at $7,539,000 after purchasing an additional 361,797 shares in the last quarter. Boston Partners increased its position in Innoviva by 90.3% in the 1st quarter. Boston Partners now owns 391,456 shares of the biotechnology company’s stock valued at $5,966,000 after buying an additional 185,784 shares in the last quarter. Marshall Wace LLP increased its position in Innoviva by 823.3% in the 2nd quarter. Marshall Wace LLP now owns 204,752 shares of the biotechnology company’s stock valued at $3,358,000 after buying an additional 182,575 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Innoviva during the 2nd quarter worth approximately $2,198,000. Finally, Wellington Management Group LLP bought a new position in Innoviva in the fourth quarter worth approximately $1,940,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on INVA shares. StockNews.com lowered Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th.

Innoviva Stock Up 0.4 %

Shares of INVA traded up $0.07 during trading hours on Monday, reaching $19.84. 5,495 shares of the stock traded hands, compared to its average volume of 570,274. Innoviva, Inc. has a 52 week low of $12.22 and a 52 week high of $20.37. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 11.98 and a beta of 0.57. The stock has a fifty day simple moving average of $19.44 and a 200 day simple moving average of $17.48. The company has a current ratio of 12.70, a quick ratio of 11.40 and a debt-to-equity ratio of 0.67.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 EPS for the quarter. The firm had revenue of $99.90 million for the quarter. Innoviva had a net margin of 44.00% and a return on equity of 33.26%. On average, equities analysts forecast that Innoviva, Inc. will post 0.5 EPS for the current year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.